Magrolimab receives FDA breakthrough therapy designation for treatment of myelodysplastic syndrome

Magrolimab is an anti-CD47 monoclonal antibody currently under investigation. Breakthrough designation was based on positive results of an ongoing Phase 1b study, which found an objective response rate of 91%, and complete remission rate of 42% for magrolimab plus azacitidine.


Biospace Inc.